COVID-19 Archives - Page 4 of 16

Developments

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using...

January 20, 2022

Developments

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...

January 18, 2022

Markets

Dawson James starts Bluejay Diagnostics at buy; PT $10

Dawson James Securities initiated coverage of Bluejay Diagnostics (NASDAQ:BJDX) with a “buy” rating and price target of $10. The stock closed at $2.74 on Jan. 11. Bluejay is focused on improving patient outcomes...

January 12, 2022

Developments

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

In a letter to shareholders, chairman and CEO, Jim Joyce of Sigyn Therapeutics (OTC:SIGY), said that in the face of a pandemic that paused and shuttered numerous clinical research programs, “we translated our vision for...

January 4, 2022

Developments

PharmaJet partner Zydus Cadila in COVID-19 vaccine expansion with Korean firm

Needle-free injection company PharmaJet’s partner, Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine, ZyCoV-D, in Korea. The plan is to manufacture more than 80...

January 4, 2022

Developments

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Altamira Therapeutics (NASDAQ:CYTO) issued a business update on Bentrio, its nasal spray for protection against airborne viruses and allergens. The company has set up contracts with wholesalers in its lead market of...

December 30, 2021

Markets

Cantor starts Cardiol at OW; PT $8

Cantor Fitzgerald launched coverage of Cardiol Therapeutics (NASDAQ:CRDL) with an “overweight” rating and price target of $8. The stock closed at $1.87 on Dec. 16. Cardiol is a clinical-stage, platform-enabled...

December 17, 2021

Executive Moves

Ondine Biomedical appoints renowned Prof Trevor Jones to lead COVID-19 advisory board

Ondine Biomedical (LSE:OBI), appointed Prof. Trevor Jones, CBE FMedSci, to lead a new advisory board on the use of its pioneering photodisinfection-based technology to prevent and treat COVID-19. Ondine’s non-antibiotic...

December 15, 2021

Developments

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate...

November 18, 2021

Markets

SVB Leerink cuts Spruce Biosciences to MP; PT to $5 from $35

SVB Leerink downgraded Spruce Biosciences (NASDAQ:SPRB) to “market perform” from “outperform” and slashed its price target to $5 from $35 after reviewing the company’s third quarter business update, speaking with...

November 16, 2021

Tag - COVID-19

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

Dawson James starts Bluejay Diagnostics at buy; PT $10

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

PharmaJet partner Zydus Cadila in COVID-19 vaccine expansion with Korean firm

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Cantor starts Cardiol at OW; PT $8

Ondine Biomedical appoints renowned Prof Trevor Jones to lead COVID-19 advisory board

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

SVB Leerink cuts Spruce Biosciences to MP; PT to $5 from $35

General

More